Wahed Invest LLC Acquires 153 Shares of Illumina, Inc. (NASDAQ:ILMN)

Wahed Invest LLC grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,695 shares of the life sciences company’s stock after buying an additional 153 shares during the period. Wahed Invest LLC’s holdings in Illumina were worth $375,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Illumina by 15.0% in the 3rd quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock worth $2,466,614,000 after purchasing an additional 2,336,935 shares during the last quarter. Capital World Investors purchased a new position in shares of Illumina in the 4th quarter worth about $271,753,000. Norges Bank purchased a new position in shares of Illumina in the 4th quarter worth about $264,636,000. Coatue Management LLC purchased a new position in shares of Illumina in the 4th quarter worth about $119,285,000. Finally, Nuance Investments LLC purchased a new position in shares of Illumina in the 4th quarter worth about $99,678,000. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 0.4 %

NASDAQ ILMN opened at $109.07 on Tuesday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a one year low of $89.00 and a one year high of $203.19. The stock has a 50 day moving average price of $114.50 and a 200-day moving average price of $127.83.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company’s quarterly revenue was down 1.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.08 EPS. On average, equities analysts forecast that Illumina, Inc. will post 1.04 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ILMN. OTR Global reissued a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Scotiabank decreased their target price on Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a research report on Monday, May 6th. Jefferies Financial Group began coverage on Illumina in a research report on Monday, June 3rd. They issued a “hold” rating and a $115.00 target price for the company. StockNews.com began coverage on shares of Illumina in a research report on Friday. They set a “buy” rating for the company. Finally, Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Tuesday, May 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $158.14.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.